Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0O8WT
|
||||
Former ID |
DIB020825
|
||||
Drug Name |
Ro0711401
|
||||
Synonyms |
compound 14a [PMID: 19233648]
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Discovery agent | Investigative | [1] | ||
Structure |
![]() |
Download2D MOL |
|||
Formula |
C18H11F3N2O3
|
||||
InChI |
InChI=1S/C18H11F3N2O3/c19-18(20,21)14-9-25-17(22-14)23-16(24)15-10-5-1-3-7-12(10)26-13-8-4-2-6-11(13)15/h1-9,15H,(H,22,23,24)
|
||||
InChIKey |
GSGDLBUOSWGZER-UHFFFAOYSA-N
|
||||
PubChem Compound ID | |||||
PubChem Substance ID | |||||
Target and Pathway | |||||
Target(s) | Metabotropicglutamate receptor 1 | Target Info | Modulator (allosteric modulator) | [1] | |
KEGG Pathway | Calcium signaling pathway | ||||
FoxO signaling pathway | |||||
Neuroactive ligand-receptor interaction | |||||
Gap junction | |||||
Long-term potentiation | |||||
Retrograde endocannabinoid signaling | |||||
Glutamatergic synapse | |||||
Long-term depression | |||||
Estrogen signaling pathway | |||||
PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
Metabotropic glutamate receptor group III pathway | |||||
Metabotropic glutamate receptor group I pathway | |||||
Endogenous cannabinoid signaling | |||||
Reactome | G alpha (q) signalling events | ||||
Class C/3 (Metabotropic glutamate/pheromone receptors) | |||||
WikiPathways | Hypothetical Network for Drug Addiction | ||||
GPCRs, Class C Metabotropic glutamate, pheromone | |||||
Gastrin-CREB signalling pathway via PKC and MAPK | |||||
GPCR ligand binding | |||||
GPCR downstream signaling | |||||
GPCRs, Other | |||||
References | |||||
REF 1 | Fluorinated 9H-xanthene-9-carboxylic acid oxazol-2-yl-amides as potent, orally available mGlu1 receptor enhancers. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1666-9. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.